Of Viagra and misplaced 'performance'
Aced with increasing antidoping tests, athletes and sportspersons may have a new performance enhancing drug Viagra.
Marywood University is conducting study, financed by the World Anti-doping agency, whether the pill, used for ereetile dysfunction among men, could help enhance performance in sports fields also.
The aim of the study the New York Times says, is to determine whether it creates unfair competitive advantage in dilating an athlete's blood vessels and unduly increasing oxygen-carrying capacity and if the agency should move to ban the drug which being currently widely used to enhance performance in the bed room.
Viagra, or sildenafil citrate, was devised to treat pulmonary hypertension in arteries of the lungs, the paper notes, explaining that it works by suppressing an enzyme that controls blood flow, allowing the vessels to relax and widen.
To read the full article, click here..
To read the ePaper, visit: http://epaper.hindustantimes.com
Marywood University is conducting study, financed by the World Anti-doping agency, whether the pill, used for ereetile dysfunction among men, could help enhance performance in sports fields also.
The aim of the study the New York Times says, is to determine whether it creates unfair competitive advantage in dilating an athlete's blood vessels and unduly increasing oxygen-carrying capacity and if the agency should move to ban the drug which being currently widely used to enhance performance in the bed room.
Viagra, or sildenafil citrate, was devised to treat pulmonary hypertension in arteries of the lungs, the paper notes, explaining that it works by suppressing an enzyme that controls blood flow, allowing the vessels to relax and widen.
To read the full article, click here..
To read the ePaper, visit: http://epaper.hindustantimes.com
Labels: antidoping tests, arteries of the lungs, controls blood flow, drug Viagra, enhance performance in sports fields, pulmonary hypertension, World Anti-doping agency
posted by PressMart Team at
11:01 AM
0 Comments
